256 related articles for article (PubMed ID: 23414583)
1. Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study.
Denis B; Gendre I; Sauleau EA; Lacroute J; Perrin P
Dig Liver Dis; 2013 Jun; 45(6):474-80. PubMed ID: 23414583
[TBL] [Abstract][Full Text] [Related]
2. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.
Leuraud K; Jezewski-Serra D; Viguier J; Salines E
Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240
[TBL] [Abstract][Full Text] [Related]
4. Immunoassay-based screening for colorectal cancer. More colonoscopies performed and more cancers detected than with Haemoccult.
Prescrire Int; 2012 Dec; 21(133):299-302. PubMed ID: 23373100
[TBL] [Abstract][Full Text] [Related]
5. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
6. The mean number of adenomas per procedure should become the gold standard to measure the neoplasia yield of colonoscopy: a population-based cohort study.
Denis B; Sauleau EA; Gendre I; Exbrayat C; Piette C; Dancourt V; Foll Y; Ait Hadad H; Bailly L; Perrin P
Dig Liver Dis; 2014 Feb; 46(2):176-81. PubMed ID: 24054769
[TBL] [Abstract][Full Text] [Related]
7. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
8. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
Malila N; Oivanen T; Hakama M
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
[TBL] [Abstract][Full Text] [Related]
9. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
10. Severe complications in colorectal cancer screening colonoscopies in the Valencian Community.
Ibáñez J; Vanaclocha-Espí M; Pérez-Sanz E; Valverde MJ; Sáez-Lloret I; Molina-Barceló A; Salas D; ;
Gastroenterol Hepatol; 2018 Nov; 41(9):553-561. PubMed ID: 30055861
[TBL] [Abstract][Full Text] [Related]
11. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
[TBL] [Abstract][Full Text] [Related]
12. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
13. Outpatient colonoscopy complications in the CDC's Colorectal Cancer Screening Demonstration Program: a prospective analysis.
Castro G; Azrak MF; Seeff LC; Royalty J
Cancer; 2013 Aug; 119 Suppl 15():2849-54. PubMed ID: 23868479
[TBL] [Abstract][Full Text] [Related]
14. Socio-geographical determinants of colonoscopy uptake after faecal occult blood test.
Dupont-Lucas C; Dejardin O; Dancourt V; Launay L; Launoy G; Guittet L
Dig Liver Dis; 2011 Sep; 43(9):714-20. PubMed ID: 21530429
[TBL] [Abstract][Full Text] [Related]
15. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies.
Stock C; Ihle P; Sieg A; Schubert I; Hoffmeister M; Brenner H
Gastrointest Endosc; 2013 Mar; 77(3):419-29. PubMed ID: 23410698
[TBL] [Abstract][Full Text] [Related]
16. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of colonoscopy in a colorectal cancer screening program with fecal immunochemical testing: a population-based observational study.
Denis B; Gendre I; Weber S; Perrin P
Endosc Int Open; 2021 Feb; 9(2):E224-E232. PubMed ID: 33553585
[No Abstract] [Full Text] [Related]
18. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study.
Denis B; Gendre I; Perrin P
J Med Screen; 2015 Jun; 22(2):76-82. PubMed ID: 25576338
[TBL] [Abstract][Full Text] [Related]
19. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.
Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC
Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470
[TBL] [Abstract][Full Text] [Related]
20. Colonoscopy requirements of population screening for colorectal cancer in New Zealand.
Green T; Richardson A; Parry S
N Z Med J; 2012 Jun; 125(1356):85-95. PubMed ID: 22729063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
